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1. W with ACS who undergo coronary angiography have similar rates of STEMI,
NSTEMI, & biomarker release despite differences in baseline characteristics.
2. Evidence based medical therapy is similar except W are less likely to receive lipid low-
ering therapy than M (62% vs. 69% p<0.03)
3. We observed an apparent gender bias in revascularization favoring more PCI/CABG in
M.
4. Treatment bias against W with ACS receiving less revascularization was not due to
gender but rather to differences in severity of epicardial coronary obstruction.
1097-97 Safety of Stress Testing Following an Acute Coronary 
Syndrome
Juhana Karha, Christopher P. Cannon, Sabina A. Murphy, Peter M. DiBattiste, C. Michael 
Gibson, Eugene Braunwald, Brigham and Women's Hospital, Boston, MA
Background: The safety of stress testing within 72 hours following an acute coronary
syndrome has not been established.We hypothesized that performance of a stress test
within 48 to 72 hours after unstable angina (UA) or non-ST segment elevation myocardial
infarction (NSTEMI) would be safe. Methods: Patients (n=1,106) were drawn from the
conservative arm of the TACTICS/TIMI 18 trial. In TACTICS, 2,220 patients with UA/
NSTEMI were treated with aspirin, heparin, and tirofiban, and randomized to an early
invasive strategy or to a conservative strategy in which cardiac catheterization was per-
formed only if the patient had objective evidence of recurrent ischemia or an abnormal
stress test performed within 48 to 72 hours. Results: Of the 847 patients undergoing
stress testing, 494 underwent an exercise treadmill test (mean ± s.d. duration: 7.6 ± 3.2
min), and 353 underwent a pharmacologic stress test with adenosine (n=122), persan-
tine (n=152), or dobutamine (n=79). Per protocol, patients who developed spontaneous
recurrent ischemia prior to stress testing underwent a cardiac catheterization instead,
and a total of 259 patients in the conservative arm did not undergo a stress test. Mortality
at 30 days was 0.94% (8/847) among the patients who underwent a stress test. One of
the deaths occurred on the day of stress testing (mortality = 0.12%). Both of the patients
who died within 24 hours of stress testing had an elevated admission troponin, and one
also had transient ST segment elevation on the admission ECG. Only one patient suf-
fered an MI on the day of stress testing. Conclusions: In patients with UA/NSTEMI
treated with aspirin, heparin, and tirofiban, performance of an exercise or a pharmaco-
logic stress test is safe within 48 to 72 hours after admission.
1097-98 Early Continuous ST Monitoring Identifies Acute 
Coronary Syndrome Patients at High Risk of Death and 
Myocardial Infarction Despite Contemporary Treatment
Andrew T. Yan, Raymond Yan, Mary Tan, David H. Fitchett, Marc Cohen, Paul W. 
Armstrong, Anatoly Langer, Shaun G. Goodman, Canadian Heart Research Centre, 
Toronto, ON, Canada, University of Toronto, Toronto, ON, Canada
Background: Previous small studies suggest continuous ST segment (Holter) monitor-
ing early after presentation can identify high risk patients with acute coronary syndromes
(ACS). However, it is unclear whether this technique remains useful in the contemporary
era of anti-thrombotic therapies.
Methods: In 2 randomized clinical trials comparing enoxaparin with unfractionated hep-
arin ± eptifibatide (INTERACT and ESSENCE ECG substudy), 853 patients with non-ST
elevation ACS underwent early continuous 96 hr Holter monitoring analyzed by an auto-
mated algorithm and reviewed by cardiologists blinded to clinical data. Outcomes at 30
days were independently adjudicated. We examined the prognostic value of Holter-
detected ischemia (HI; >0.1 mV ST deviation >1 min duration).
Results: Of the 853 patients enrolled, 261 (30.6%) had HI (see Table). 
After adjusting for other prognosticators including cardiac biomarker status, HI remained 
a strong predictor of death/MI [OR 3.5 (1.9-6.4), P<0.001] and all-cause mortality [OR 
4.3 (1.6-11.7), P=0.004] at 30 days. In multivariable analysis, renal dysfunction and ST 
deviation were independently associated with HI, while enoxaparin treatment significantly 
reduced the incidence of HI [OR 0.41 (0.28-0.60), P<0.001].
Conclusion: HI is a powerful independent predictor of mortality and MI among ACS 
patients treated in the modern era. This simple tool provides incremental prognostic 
value over the conventional risk stratification of non-ST elevation ACS patients.
1097-99 Racial Differences in Utilization of Primary Prevention 
Strategies and Cardiac Catheterization Following First 
Myocardial Infarction
Jon H. Mojares, Michael P. Hudson, Michelle Jankowski, Keisha R. Sandberg, Henry E. 
Kim, Henry Ford Heart and Vascular Institute, Detroit, MI
Background: Primary prevention strategies such as aspirin, ACE inhibitors and lipid low-
ering drugs may reduce the incidence of myocardial infarction (MI) in patients without
known coronary heart disease. We assessed the hypothesis that racial differences exist
in the implementation of primary prevention strategies.
Methods: In 1571 patients presenting between 1997-2001 with first acute MI and no
prior angina, MI or revascularization, we investigated the presence of racial differences in
the use of primary prevention.
Results: African American (AA) versus Caucasian patients had higher rates of diabetes
and hypertension with lower rates of hyperlipidemia (see table below). Rates of aspirin,
beta blocker, and lipid lowering drug use did not significantly differ according to race;
however, AA patients were more likely to receive ACE inhibitors prior to MI and less likely
to undergo post-MI catheterization.
Conclusions: Minimal differences exist in the use of MI primary prevention strategies
between Caucasian and AA patients. Following first MI, however, AA patients are less
likely to undergo aggressive evaluation with cardiac catheterization and revasculariza-
tion.
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1098-77 TIMI, PURSUIT and GRACE Risk Scores in Acute 
Coronary Syndromes: Comparison and Interaction With 
Myocardial Revascularization
Pedro Araujo Goncalves, Jorge Ferreira, Carlos Aguiar, Marisa Trabulo, Ricardo Seabra-
Gomes, Hospital de Santa Cruz, Carnaxide, Portugal
Background: Regarding prognosis, patients with a non-ST elevation acute coronary syn-
drome (ACS) are a very heterogeneous population, with varying risks of early and long-
term adverse events. Early risk stratification at admission seems to be essential for a tai-
lored therapeutic strategy.
Objective: We sought to compare the prognostic value of three ACS risk scores (RS) and
their ability to predict benefit from myocardial revascularization performed during the ini-
tial hospitalization.
Methods: We studied 460 consecutive patients admitted to our CCU with an ACS. For
each patient, the TIMI, PURSUIT and GRACE RS were calculated. Their prognostic
value was evaluated by the combined incidence of death (D) or myocardial infarction (MI)
at 1 year. The best cut-off value for each RS, was used to assess the impact of myocar-
dial revascularization on D or MI at 1 year.
Results: D or MI at 1 year was 15.4% (32 D/ 49 MI). The best predictive accuracy for D or
Demographics 
M (1123) W (601) P value
Age yrs 62 67 <0.0001
Heart Failure % 17 25 <0.0001
BP systolic mmHg 138 142 0.004
Tobacco % 70 50 <0.0001
Cardiac Enzymes + 72 71 0.44
PCI or CABG % 52 41 <0.0001
PCI % 45 33 <0.0001
CABG % 7.3 8.2 0.49
Angiography %
Normal/mild CAD 31 43 <0.0001
1 vessel 18 16 0.20
2 vessel 16 16 0.88
3 vessel 22 18 0.04
Left main 3.3 2.2 0.18
30-day outcomes Patients without 
Holter Ischemia
(N=592)
Patients with 
Holter Ischemia
(N=261)
Odds Ratio [OR] 
(95% CI)
P value
Death/Myocardial 
Infarction (MI)
3.4% 10.7% 3.4 (1.9-6.2) <0.001
Death 1.0% 5.0% 5.1 (1.9-13.6) 0.001
Caucasian (n=832) African-American (n=739) p-value 
Hypertension 50% 71% <0.001
Diabetes 22% 30% 0.0007
Smoking 61% 61% 0.86
Hyperlipidemia 36% 25% <0.0001
Lipid Lowering Drugs 16% 13% 0.19
Aspirin 21% 19% 0.33
Beta-Blockers 13% 13% 0.19
ACE inhibitors 18% 22% 0.03
Catheterization 61% 43% <0.0001
